STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies such as interferon-alfa and STI571 may interfere with the
growth of cancer cells. It is not yet known if STI571 is more effective than interferon alfa
plus cytarabine for chronic myelogenous leukemia.
PURPOSE: Randomized phase III trial to compare the effectiveness of STI571 with that of
interferon alfa plus cytarabine in treating patients who have newly diagnosed chronic
myelogenous leukemia.